XTALPI Holdings (02228.HK) Surges Over 8% in Early Trading as Business Expands from AI-Driven Drug Discovery to Broad AI for Science (AI4S) Platform

According to the Zhongtong Finance APP, XtalPi Holdings Limited (02228) rose over 8% in early trading. As of the time of writing, it was up 6.98%, trading at HK$10.12, with a turnover of HK$129 million.

In terms of news, at the beginning of last month, MiRXES, a company specializing in early cancer screening, announced a collaboration with XtalPi, an AI pharmaceutical platform company. The two parties aim to integrate their respective strengths in early detection and drug development to jointly explore an "integrated diagnosis and treatment" solution targeting cancers with high incidence in Asia. This move is considered an important attempt to consolidate the value chain for cancer prevention and control.

Shenwan Hongyuan released a research report stating that XtalPi Holdings Limited, relying on its core technology of "physical computing + AI + robotics," has built a complete closed loop for early-stage drug discovery from algorithms, engines to automated laboratories. The company's business has expanded from AI-driven drug discovery to a broader "AI4S" platform. Its underlying technology not only accelerates various stages of innovative drug development but also has the potential to extend into fields such as new materials, demonstrating strong technical breadth and platform value. Initiate coverage with a "Buy" rating.